曲妥珠单抗联合新辅助化疗同期或序贯放疗在HER2阳性局部晚期不可手术乳腺癌中的II期随机对照试验
该II期随机试验纳入118例新诊断不可手术的HER2阳性局部晚期乳腺癌患者,随机接受曲妥珠单抗联合新辅助化疗(A臂)或曲妥珠单抗联合新辅助同期化放疗(B臂)。两臂病理完全缓解率分别为46.6%和50.9%(P=.64),3年无事件生存率和总生存率均无显著差异,但B臂中位治疗时长显著缩短(193.1天 vs 262.9天,P<.0001),且未观察到心脏毒性。
要点
- 同期化放疗联合曲妥珠单抗未显著提高病理完全缓解率(50.9% vs 46.6%,P=.64)。
- 同期化放疗组中位治疗时长显著缩短(193.1天 vs 262.9天,P<.0001)。
- 同期化放疗组3级放射性皮炎发生率为5.5%,未观察到心脏毒性。
核心结论
- 曲妥珠单抗联合新辅助同期化放疗可行且安全,显著缩短总治疗时长,且不损害生存。
研究设计与样本
- II期随机对照试验,纳入118例新诊断不可手术的HER2阳性局部晚期乳腺癌患者,1:1随机分入A臂(62例)或B臂(56例)。
- A臂接受曲妥珠单抗联合新辅助化疗后序贯放疗(50 Gy),B臂在紫杉醇和曲妥珠单抗期间同期放疗(46 Gy至乳腺和区域淋巴结)后行乳房切除术。
主要发现
- A臂和B臂病理完全缓解率分别为46.6%和50.9%(P=.64),亚组间无差异。
- 中位随访36个月,3年无事件生存率A臂79.8%、B臂76.8%(P=.89),总生存率A臂88.7%、B臂87.4%(P=.63)。
- 中位治疗时长B臂显著短于A臂(193.1天 vs 262.9天,P<.0001)。
- 手术伤口并发症A臂6.9%(4/58)、B臂16.4%(9/55)(P=.15)。
- 仅B臂观察到3级放射性皮炎5.5%(3/55)和中性粒细胞减少3.6%(2/55),未观察到心脏毒性。
关键数值与推荐
- 病理完全缓解率为主要终点,A臂46.6% vs B臂50.9%(P=.64)。
- 3年无事件生存率A臂79.8% vs B臂76.8%(P=.89);总生存率A臂88.7% vs B臂87.4%(P=.63)。
- 中位治疗时长A臂262.9天 vs B臂193.1天(P<.0001)。
临床怎么用
- 对于治疗效率优先的选定HER2阳性局部晚期不可手术乳腺癌患者,可考虑曲妥珠单抗联合新辅助同期化放疗以缩短治疗时长。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of neoadjuvant concurrent chemoradiation therapy (NACCRT) with anti-Human epidermal Growth Factor Receptor 2 (HER2) therapy in locally advanced breast cancer (LABC) remains unexplored. We conducted a phase 2 randomized trial to evaluate whether NACCRT combined with trastuzumab improves pathologic complete response (pCR) compared with standard neoadjuvant chemotherapy (NACT) in patients with HER2-positive inoperable LABC. METHODS AND MATERIALS: Patients with newly diagnosed, inoperable HER2-positive LABC were randomized 1:1 to receive NACT with trastuzumab (arm A) or NACCRT with trastuzumab (arm B). Both arms received anthracycline- and taxane-based chemotherapy with trastuzumab. Arm B received concurrent radiation therapy (46 Gy to the breast and regional nodes) during paclitaxel and trastuzumab, followed by mastectomy, whereas arm A received sequential radiation therapy (50 Gy). The primary endpoint was pCR; secondary endpoints included survival, operability, toxicity, and treatment duration. RESULTS: A total of 118 patients were evaluated (arm A, n = 62; arm B, n = 56). Median age was 50 years, and all patients had stage III disease. pCR rates were 46.6% in arm A and 50.9% in arm B (P = .64), with no differences between subgroups (hormone receptor status, menopausal status, tumor size, and stage grouping). The median follow-up was 36 months. Three-year event-free survival was 79.8% in arm A and 76.8% in arm B (P = .89), whereas overall survival was 88.7% in arm A and 87.4% in arm B (P = .63). Median treatment duration was significantly shorter with NACCRT (193.1 vs 262.9 days; P < .0001). Surgical wound morbidity occurred in 6.9% (4/58) of arm A versus 16.4% (9 of 55) of arm B (P = .15). Grade 3 radiation dermatitis of 5.5% (3 of 55) and neutropenia of 3.6% (2 of 55) were observed only in arm B. No cardiac toxicity was observed. CONCLUSIONS: NACCRT with trastuzumab is feasible and safe, significantly shortens overall treatment duration, and does not compromise survival. This strategy warrants further evaluation in selected patients where treatment efficiency is a priority.
引用
- Iyer P, Krishnamurthy A, Velusamy S, et al. Neoadjuvant Chemotherapy With Trastuzumab With or without Concurrent Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Inoperable Breast Cancer-A Phase 2 Randomized Controlled Trial (NEOTRAC STUDY). Int J Radiat Oncol Biol Phys. 2026. PMID: 42431330. doi:10.1016/j.ijrobp.2026.06.3086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。